SG11202002123XA - Compositions and methods for treating liver cancer - Google Patents
Compositions and methods for treating liver cancerInfo
- Publication number
- SG11202002123XA SG11202002123XA SG11202002123XA SG11202002123XA SG11202002123XA SG 11202002123X A SG11202002123X A SG 11202002123XA SG 11202002123X A SG11202002123X A SG 11202002123XA SG 11202002123X A SG11202002123X A SG 11202002123XA SG 11202002123X A SG11202002123X A SG 11202002123XA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- liver cancer
- treating liver
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/844—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762578071P | 2017-10-27 | 2017-10-27 | |
| PCT/US2018/057731 WO2019084418A1 (en) | 2017-10-27 | 2018-10-26 | Compositions and methods for treating liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002123XA true SG11202002123XA (en) | 2020-04-29 |
Family
ID=64453576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002123XA SG11202002123XA (en) | 2017-10-27 | 2018-10-26 | Compositions and methods for treating liver cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200353022A1 (en) |
| EP (1) | EP3700544A1 (en) |
| JP (1) | JP2021501150A (en) |
| KR (1) | KR20200078483A (en) |
| CN (1) | CN111278448A (en) |
| AR (1) | AR113805A1 (en) |
| AU (1) | AU2018355519A1 (en) |
| BR (1) | BR112020007494A2 (en) |
| CA (1) | CA3075294A1 (en) |
| MX (1) | MX2020003388A (en) |
| SG (1) | SG11202002123XA (en) |
| TW (1) | TWI817958B (en) |
| WO (1) | WO2019084418A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2170959B1 (en) | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| TW201900193A (en) * | 2017-04-28 | 2019-01-01 | 美商默沙東藥廠 | Biomarkers for cancer treatment |
| CN114191547A (en) * | 2021-12-23 | 2022-03-18 | 中山大学 | Application of combination of ranvatinib and PD-1 monoclonal antibody in preparation of anti-liver cancer drugs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU2695101A (en) | 2000-01-21 | 2001-07-31 | Biovex Ltd | Virus strains |
| EP2170959B1 (en) | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| MX341076B (en) | 2011-03-31 | 2016-08-04 | Merck Sharp & Dohme | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments. |
| JP6457940B2 (en) | 2012-08-30 | 2019-01-23 | アムジエン・インコーポレーテツド | Method for treating melanoma using herpes simplex virus and immune checkpoint inhibitors |
| KR102504758B1 (en) * | 2014-07-16 | 2023-02-28 | 트랜스진 | Combination of oncolytic virus with immune checkpoint modulators |
| WO2016008976A1 (en) * | 2014-07-16 | 2016-01-21 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
| WO2016196173A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer |
| WO2017156349A1 (en) * | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| AU2017375958A1 (en) * | 2016-12-12 | 2019-07-04 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| TW201900193A (en) * | 2017-04-28 | 2019-01-01 | 美商默沙東藥廠 | Biomarkers for cancer treatment |
-
2018
- 2018-10-26 WO PCT/US2018/057731 patent/WO2019084418A1/en active Application Filing
- 2018-10-26 SG SG11202002123XA patent/SG11202002123XA/en unknown
- 2018-10-26 MX MX2020003388A patent/MX2020003388A/en unknown
- 2018-10-26 CN CN201880068853.5A patent/CN111278448A/en active Pending
- 2018-10-26 BR BR112020007494-2A patent/BR112020007494A2/en unknown
- 2018-10-26 KR KR1020207008272A patent/KR20200078483A/en not_active Application Discontinuation
- 2018-10-26 EP EP18807758.0A patent/EP3700544A1/en active Pending
- 2018-10-26 AR ARP180103133A patent/AR113805A1/en unknown
- 2018-10-26 JP JP2020523323A patent/JP2021501150A/en active Pending
- 2018-10-26 US US16/759,476 patent/US20200353022A1/en not_active Abandoned
- 2018-10-26 CA CA3075294A patent/CA3075294A1/en active Pending
- 2018-10-26 AU AU2018355519A patent/AU2018355519A1/en active Pending
- 2018-10-29 TW TW107138162A patent/TWI817958B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI817958B (en) | 2023-10-11 |
| US20200353022A1 (en) | 2020-11-12 |
| EP3700544A1 (en) | 2020-09-02 |
| RU2020111709A (en) | 2021-11-29 |
| CN111278448A (en) | 2020-06-12 |
| AR113805A1 (en) | 2020-06-10 |
| KR20200078483A (en) | 2020-07-01 |
| CA3075294A1 (en) | 2019-05-02 |
| WO2019084418A1 (en) | 2019-05-02 |
| JP2021501150A (en) | 2021-01-14 |
| TW201922273A (en) | 2019-06-16 |
| BR112020007494A2 (en) | 2020-11-03 |
| MX2020003388A (en) | 2020-08-03 |
| RU2020111709A3 (en) | 2022-04-26 |
| AU2018355519A1 (en) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267247B (en) | Compositions and methods for treating cancer | |
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL264034A (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| IL266053A (en) | Compositions and methods for treating ezh2-mediated cancer | |
| EP3507304C0 (en) | Compositions and methods for treating cancer with duocars | |
| IL304820A (en) | Compositions and methods for treating cancer | |
| EP3687981A4 (en) | Compositions and methods for treating cancer | |
| PT3377516T (en) | Methods and compositions for treating cancer | |
| IL265786A (en) | Compositions and methods for enhancing cancer radiotherapy | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| IL271326A (en) | Compositions and methods for enhancing cancer radiotherapy | |
| EP3462883A4 (en) | Compositions and methods for treating cancer | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| EP3600302A4 (en) | Methods and compositions for treating cancer | |
| EP3612222A4 (en) | Compositions and methods for treating cancer | |
| EP3528798A4 (en) | Compositions and methods for treating cancer | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| EP3541421A4 (en) | Compositions and methods for treating cancer | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| EP3638293A4 (en) | Methods and compositions for treating cancer | |
| EP3468546A4 (en) | Compositions and methods for treating cancer | |
| EP3714043A4 (en) | Compositions and methods for treating cancer | |
| EP3585398A4 (en) | Compositions and methods for treating cancer | |
| IL255638A (en) | Compositions and methods for treating cancer |